Comparative analysis of prostatoliths and corpora amylacea effects on the immunophenotype of prostate cancer

Keywords: prostate cancer, prostatic calculi, corpora amylacea, immunophenotype.


Prostate cancer (PC) has the highest incidence rate in a male population all over the world. The aim of the work was to compare the effect of prostatic calculi and corpora amylacea on the immunophenotype of PC. 10 samples of PC with calculi, 20 samples with a corpora amylacea and 30 control samples were used for this study. Histochemical techniques (alizarin red, von Kossa, Congo red stainings), scanning electron microscopy with energy dispersive X-ray spectroscopy and immunohistochemistry (antibodies against AR, p53, Casp3, Bax, MMP1, HSP70, Hsp90, VEGF, CD68 and MPO) were used. Statistical processing was carried out by the Shapiro-Wilk test, Mann-Whitney U-test and Student t-test. The presence of intraluminal inclusions is accompanied by increased expression of proapoptotic markers Casp3 and Bax by tumor tissue. It was found that in the group of samples with intraluminal inclusions, the expression level of VEGF and Hsp90 is lower in comparison to control group (p<0.05). The difference between VEGF and Hsp90 expression in the PC with calculi and PC with corpora amylacea was not detected (p> 0.05). In the future, it is planned to study the effect of intraluminal inclusions on the development of bone metastasis of PC.

Author Biography

A.M. Piddubnyi

Piddubnyi Artem, PhD student, Departmen of Pathology, Sumy State University, ORCID 0000-0002-6508-0131  +38 095 149 97 14


1. Romaniuk, A. M., Moskalenko, R. A., Piddubnyi, A. M., & Sikora, V. V. (2016). Analiz zakhvoryuvanosti na zloyakisni puchlyny peredmichurovoi zalozy v Sumskiy oblasti [Analysis of the incidence of malignant tumors of the prostate in Sumy region]. Visnyk problem biologii i medycyny – Bulletin of Biology and Medicine, 2 (1), 94–97.

2. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer journal for clinicians, 68 (6), 394–424 doi: 10.3322/caac.21492.

3. Hyun, J. S. (2018). Clinical Significance of Prostatic Calculi: A Review. World Journal of Mens Health, 36 (1), 15–21 doi: 10.5534/wjmh.17018.

4. Pernar, C. H., Ebot, E. M., Wilson, K. M., & Mucci, L. A. (2018). The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 8 (12), а030361 doi: 10.1101/cshperspect.a030361.

5. Roberts, R. O., Bergstralh, E., Bass, S. E., Lieber, M. M., & Jacobsen, S. J. (2004). Prostatitis as a Risk Factor for Prostate Cancer. Epidemiology, 15 (1), 93–99, doi: 10.1097/01.ede.0000101022.38330.7c.

6. Stark, T., Livas, L., & Kyprianou, N. (2015). Inflammation in prostate cancer progression and therapeutic targeting. Translational Andrology and Urology, 4 (4), 455–463. doi: 10.3978/j.issn.2223-4683.2015.04.12.
How to Cite
Piddubnyi, A. (2019). Comparative analysis of prostatoliths and corpora amylacea effects on the immunophenotype of prostate cancer. Reports of Vinnytsia National Medical University, 23(1), 64-69.